Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2010
09/16/2010US20100233249 Contraceptive methods and compositions related to proteasomal interference
09/16/2010US20100233246 Adhesive tissue repair patch and collagen sheets
09/16/2010US20100233244 Smoking Withdrawal Combination Wafer
09/16/2010US20100233241 Ophthalmic drug delivery system and applications
09/16/2010US20100233238 Medical Devices Having Nanoporous Coatings for Controlled Therapeutic Agent Delivery
09/16/2010US20100233236 Drug coated expandable devices
09/16/2010US20100233232 Fatty-acid based particles
09/16/2010US20100233231 Use of cryogenic processing to obtain a substantially-thickened formulation
09/16/2010US20100233229 In-vivo indwelling device
09/16/2010US20100233228 Drug-Eluting Medical Device
09/16/2010US20100233226 Drug-eluting nanowire array
09/16/2010US20100233225 Method of surface coating devices to incorporate bioactive molecules
09/16/2010US20100233223 Powder-Free Antimicrobial Coated Glove
09/16/2010US20100233217 Organic compounds
09/16/2010US20100233200 Vector encoding therapeutic polypeptide and safety elements to clear transduced cells
09/16/2010US20100233198 Use of oligosaccharides containing n-acetyllactosamine for maturation of immune responses in neonates
09/16/2010US20100233194 Treatment of neovascular ocular disease states
09/16/2010US20100233193 Systemic administration of nac for vaccination prophylaxis
09/16/2010US20100233190 Targeted polymeric prodrugs containing multifunctional linkers
09/16/2010US20100233187 Gene products differentially expressed in cancerous cells
09/16/2010US20100233185 Caries Risk Test for Predicting and Assessing the Risk of Disease
09/16/2010US20100233172 Methods of inhibiting quiescent tumor proliferation
09/16/2010US20100233171 Differential Drug Sensitivity
09/16/2010US20100233166 Novel ido inhibitors and methods of use
09/16/2010US20100233164 Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
09/16/2010US20100233158 Induction of immune tolerance
09/16/2010US20100233156 Treating Central Nervous System Injury with Beta and Gamma Secretase Inhibitors
09/16/2010US20100233152 Use of HMGB proteins and nucleic acids that code therefor
09/16/2010US20100233145 Composition used as a nutritional supplement and medication for the treatment of degenerative visual disorders and inflammation
09/16/2010US20100233141 Compositions And Methods For The Delivery Of Biologically Active RNAs
09/16/2010US20100233129 Prevention and treatment of secondary infections following viral infection
09/16/2010US20100233126 Polypeptide
09/16/2010US20100233123 Phosphothiophene and phosphothiazole hcv polymerase inhibitors
09/16/2010US20100233122 Novel benzimidazole derivatives
09/16/2010US20100233120 Hepatitis C Virus Inhibitors
09/16/2010US20100233116 Organic compounds
09/16/2010US20100233115 Multilayer Fibrous Polymer Scaffolds, Methods of Production and Methods of Use
09/16/2010US20100233111 Gastropod biological fluid, method of making and refining and use
09/16/2010US20100233109 Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using a1-adrenoceptor agonists
09/16/2010US20100233107 Medicated toning lotion
09/16/2010US20100233106 Small-molecule modulators of melanin expression
09/16/2010US20100233104 Amino-Acid Functional Siloxanes, Methods Of Preparation and Applications
09/16/2010US20100233099 Device for intranasal administration
09/16/2010US20100233091 Pyrazine Derivatives with Extended Conjugation and Methods of Using the same in Optical Applications
09/16/2010US20100233087 Cyp1b1 nucleic acids and methods of use
09/16/2010US20100233086 Compounds for use in imaging, diagnosing and/or treatment of diseases of the central nervous system or of tumors
09/16/2010US20100233083 Microparticles comprising a crosslinked polymer
09/16/2010DE112008002647T5 Antidiarrhöische Zusammensetzung, Produkte, die diese enthalten, und Verfahren zum Schutz vor Diarrhö Antidiarrheal composition, products containing them, and methods for protection against diarrhea
09/16/2010DE102009012423A1 Zubereitung auf Ölbasis Preparation oil-based
09/16/2010DE102009012314A1 Oxo-heterocyclisch substituierte Alkylcarbonsäuren und ihre Verwendung Oxo-heterocyclic-substituted alkyl carboxylic acids and their use
09/16/2010DE102009001438A1 New carbonylamino-substituted anilino-pyrimidine compounds are tyrosine kinase-2 inhibitors, useful for treating diseases associated with inflammatory conditions e.g. bronchitis, rheumatoid arthritis, psoriasis and Guillain Barre syndrome
09/16/2010CA2792484A1 Implantable device for long-term delivery of drugs
09/16/2010CA2767942A1 Method of use of vitamin k as energy enhancer in diverse disease states
09/16/2010CA2760999A1 Prebiotic oligosaccharides
09/16/2010CA2755314A1 New crystals of a benzoylbenzeneacetamide derivative
09/16/2010CA2755274A1 Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide
09/16/2010CA2755245A1 Compositions and methods for the delivery of biologically active rnas
09/16/2010CA2755197A1 Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases
09/16/2010CA2755191A1 Kinase protein binding inhibitors
09/16/2010CA2755157A1 10-amino-1,2,3,4-tetrahydropyrido[2,1-a]isoindol-6(10bh)-one derivatives, method for preparing same, and therapeutic uses thereof
09/16/2010CA2755121A1 Combination therapy with thiocolchicine derivatives
09/16/2010CA2755120A1 7-cycloalkylaminoquinolones as gsk-3 inhibitors
09/16/2010CA2755118A1 Preventive or therapeutic agents for optic nerve disorders comprising 4,6-dichloro-1h-indole-2-carboxylic acid derivatives or salts thereof as active ingredients
09/16/2010CA2755084A1 Omega-3 enriched fish oil-in-water parenteral nutrition emulsions
09/16/2010CA2755061A1 Pyrimidine derivatives as mtor inhibitors
09/16/2010CA2755045A1 Pyrrolo [2, 3-b] pyridine derivatives for the inhibition of raf kinases
09/16/2010CA2755004A1 Substituted 2-mercaptoquinoline-3-carboxamides as kcnq2/3 modulators
09/16/2010CA2755002A1 Substituted 2-mercapto-3-aminopyridines as kcnq2/3 modulators
09/16/2010CA2754998A1 Substituted nicotinamides as kcnq2/3 modulators
09/16/2010CA2754946A1 Bis aromatic compounds for use as ltc4 synthase inhibitors
09/16/2010CA2754943A1 Substituted 3-amino-2-mercaptoquinolines as kcnq2/3 modulators
09/16/2010CA2754941A1 Bis aromatic compounds for use as ltc4 synthase inhibitors
09/16/2010CA2754936A1 Bis aromatic compounds for use as ltc4 synthase inhibitors
09/16/2010CA2754934A1 Substituted 3-aminoisoxazolopyridines as kcnq2/3 modulators
09/16/2010CA2754922A1 Administration of intravenous ibuprofen
09/16/2010CA2754913A1 Pharmaceutical combinations comprising rdea119/bay 869766 for the treatment of specific cancers
09/16/2010CA2754909A1 Combination of an indazolylaminopyrrolotriazine and taxane for cancer treatment
09/16/2010CA2754904A1 Benzofuran derivatives
09/16/2010CA2754902A1 Essential fatty acid compounds
09/16/2010CA2754901A1 Compositions and methods for prophylaxis and treatment of addictions
09/16/2010CA2754897A1 External preparation containing analgesic/anti-inflammatory agent
09/16/2010CA2754891A1 Treatment of pancreatic cancer
09/16/2010CA2754890A1 Novel bicyclic heterocycles
09/16/2010CA2754860A1 Compositions comprising a fatty acid oil mixture and a surfactant, and methods and uses thereof
09/16/2010CA2754853A1 Immediate release pharmaceutical compositions comprising oxycodone and naloxone
09/16/2010CA2754825A1 Use of rosuvastatin lactols as medicaments
09/16/2010CA2754808A1 Prodrug forms of kinase inhibitors and their use in therapy
09/16/2010CA2754804A1 Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as dhodh inhibitors
09/16/2010CA2754794A1 Compounds for the treatment of metabolic disorders
09/16/2010CA2754791A1 Compounds for the treatment of metabolic disorders
09/16/2010CA2754790A1 Novel coprinus comatus and tremella mesenterica mushroom strains, products and extracts thereof and compositions comprising them
09/16/2010CA2754787A1 Use of atorvastatin lactols as medicaments
09/16/2010CA2754785A1 Addition salts of tromethamine with azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
09/16/2010CA2754781A1 Bis aromatic compounds for use as ltc4 synthase inhibitors
09/16/2010CA2754709A1 Compounds for the treatment of metabolic disorders
09/16/2010CA2754688A1 Novel isoindolin-1-one derivative
09/16/2010CA2754685A1 Substituted indazole amides
09/16/2010CA2754681A1 Benzofuranyl derivatives used as glucokinase inhibitors
09/16/2010CA2754623A1 Oil-based preparation containing antiprotozoal triazines and anthelmintic cyclodepsipeptides
09/16/2010CA2754613A1 Piperazine compound capable of inhibiting prostaglandin d synthase
1 ... 2090 2091 2092 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 ... 7860